Preoperative treatment of locally advanced esophageal carcinoma
- 2 October 2013
- journal article
- review article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 43 (6), 1745-1753
- https://doi.org/10.3892/ijo.2013.2118
Abstract
Esophageal cancer (EC) is an aggressive malignancy with increasing incidence worldwide. Surgery is still the most effective treatment, however, both the high rate of local and distant recurrences and surgery-related complications led us to investigate new preoperative strategies. In this review, we discuss the role of neoadjuvant therapy for locally advanced EC with a focus on preoperative chemoradiation (trimodality treatment). Furthermore, the last fifteen years of published literature and our experience have been also reviewed. In the preoperative setting, few trials have reported a significant benefit with fluoropyrimidine and platinum compound-based neoadjuvant chemotherapy, compared to surgery alone. A large number of phase III trials and meta-analyses have demonstrated improved outcomes with preoperative chemoradiation vs. neoadjuvant chemotherapy or surgery alone. Therefore, trimodality therapy can be considered the most effective option in the management of locally advanced EC. Addition of drugs targeting VEGF or HER2 to standard chemotherapy appears to be feasible but needs to be explored more accurately. FDG-PET may predict both response to neoadjuvant treatments and prognosiKeywords
This publication has 65 references indexed in Scilit:
- SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagusBMC Cancer, 2011
- A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancerBritish Journal of Cancer, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Review: Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancersTherapeutic Advances in Medical Oncology, 2009
- Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Review of Meta‐AnalysesWorld Journal of Surgery, 2009
- Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric JunctionJournal of Clinical Oncology, 2009
- Complete Pathologic Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Is Associated With Enhanced SurvivalThe Annals of Thoracic Surgery, 2009
- EGFR-targeted anti-cancer drugs in radiotherapy: Preclinical evaluation of mechanismsRadiotherapy and Oncology, 2007
- Estimates of the cancer incidence and mortality in Europe in 2006Annals of Oncology, 2007
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002